文献速递乳腺癌

第三代芳香化酶抑制剂对比他莫昔芬一线治疗HR阳性晚期乳腺癌的荟萃分析

Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.
PubMed 文献 · Eur J Cancer · 2021-01-07

该荟萃分析纳入3项随机对照试验的个体患者数据及1项试验报告数据,共2296例患者,其中1560例(68%)为HR阳性晚期乳腺癌。

要点

  • HR阳性晚期乳腺癌一线内分泌治疗中,芳香化酶抑制剂较他莫昔芬显著改善无进展生存。
  • 临床获益率显著偏向芳香化酶抑制剂,但获益持续时间无显著延长。
  • 总生存无显著差异,无进展生存获益未转化为生存改善。

核心结论

  • 第三代芳香化酶抑制剂使更多患者获得临床获益,但肿瘤控制时间未显著延长,无进展生存获益未转化为总生存改善。

研究设计与样本

  • 荟萃分析纳入3项随机对照试验(EORTC、Study 0027、Study 0030)的匿名的个体患者数据,另1项试验(Femara Study PO25)从临床研究报告获取HR阳性患者的OR或HzR及置信区间。
  • 共获得2296例患者数据,其中1560例(68%)为HR阳性晚期乳腺癌。

主要发现

  • 临床获益率的OR为1.56,偏向芳香化酶抑制剂(p<0.001)。
  • 总生存的HzR为1.05,芳香化酶抑制剂与他莫昔芬无显著差异(p=0.42)。

临床怎么用

  • 支持第三代芳香化酶抑制剂作为HR阳性晚期乳腺癌绝经后患者一线内分泌治疗选择,但应知晓其无进展生存获益未转化为总生存改善。

局限性

  • 原始试验中6.8%至55%的肿瘤HR状态未知或阴性,本分析仅限HR阳性肿瘤。
  • 部分试验数据来自临床研究报告而非个体患者数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Four randomised controlled trials (RCTs) in postmenopausal women with advanced breast cancer (ABC) comparing aromatase inhibitors (AIs) versus the selective estrogen receptor modulator tamoxifen, each individually reported significantly longer progression-free survival (PFS) but none showed a significant difference in overall survival (OS). In these trials between 6.8% and 55% of tumours were hormone receptor (HR) status unknown or negative. This meta-analysis restricted the comparison to HR-positive (HR+) tumours. METHODS: Anonymised individual patient data were obtained from three RCTs, EORTC (exemestane versus tamoxifen), Study 0027 and Study 0030 (both anastrozole versus tamoxifen). For the remaining RCT (Femara Study PO25; letrozole versus tamoxifen), odds ratio (OR) or hazard ratio (HzR), with confidence intervals were obtained from the clinical study report, for patients with HR+ tumours, in addition to published data. In total, data were obtained from 2296 patients; 1560 (68%) had HR+ ABC. FINDINGS: The OR for clinical benefit rate was 1.56, in favour of AIs (p < 0.001). The duration of clinical benefit was not significantly increased by AIs (HzR 0·88; p = 0.08). For PFS the HzR (0.82) was in favour of AIs (p = 0·007). However, for OS the HzR (1.05) was not significantly different between AIs and tamoxifen (p = 0.42). INTERPRETATION: Although third generation AIs put significantly more patients into 'clinical benefit', their tumours were not controlled for significantly longer. Overall, while this resulted in a significantly greater PFS in favour of the AIs, this did not translate into improvement in OS.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Robertson JFR, Paridaens RJ, Lichfield J, et al. Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer. Eur J Cancer. 2021. PMID: 33418233. doi:10.1016/j.ejca.2020.11.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。